Zhejiang Garden Biopharmaceutical Co Ltd. Stock Analysis 300401.SZ

Zhejiang Garden Biopharmaceutical Co., Ltd. engages in the research, development, production and sales of vitamin D3 upstream and downstream series products. The company is headquartered in Jinhua, Zhejiang and currently employs 1,163 full-time employees. The company went IPO on 2014-10-09. The firm operates two segments. The Vitamin segment mainly produces lanolin cholesterol, vitamin D3, 25-hydroxyvitamin D3, vitamin A, and others. The Pharmaceutical segment focuses on the research and development, production and sales of high-tech barrier formulation products in the fields of chronic diseases such as cardiovascular and nervous systems, and its products include valsartan amlodipine tablets (I), doxofloxline injection, levofloxacin tablets, and others. The firm principally conducts its business in domestic market.